Current Report Filing (8-k)
February 10 2017 - 8:52AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 10, 2017
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer
Identification No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure
On
February 10, 2017, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s President and
Chief Executive Officer, James S. Manuso, Ph.D., will be presenting at the BIO CEO & Investor Conference 2017. Dr. Manuso
is scheduled to present at 1:00 p.m. Eastern Standard Time on Monday, February 13, 2017. The Conference is sponsored by the Biotechnology
Innovation Organization (BIO) and will be held at the Waldorf Astoria Hotel, New York, New York on February 13 and 14, 2017.
The
slide presentation that Dr. Manuso will be using at the conference is attached as Exhibit 99.1 and is being furnished and not
filed pursuant to Item 7.01 of Form 8-K. The presentation will be available by live webcast that can be accessed by clicking on
the investors tab on the Company’s web-site (www.respirerx.com), and following the links and instructions in the press release
announcing this presentation or by going to:
http://www.veracast.com/webcasts/bio/ceoinvestor2017/36118482417.cfm
The
webcast replay will be available one hour after conclusion of the live event and the replay will expire on May 15, 2017.
The press release announcing the Company’s participation in the conference is attached as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RESPIRERX PHARMACEUTICALS INC.
|
Date:
February 10, 2017
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
Jeff
E. Margolis
|
|
|
Vice
President, Treasurer and Secretary
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Exhibit
Description
|
|
|
|
99.1
|
|
Slide
Presentation*
|
99.2
|
|
Press
Release dated February 10, 2017*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024